Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches.

Shreeya PatelThitima KongnakornAndreas NikolaouYassir JavaidRuth Mokgokong

Published in: Journal of medical economics (2023)

Screening for NVAF at ≥75 years of age could result in fewer NVAF-related strokes. NVAF screening is cost-effective and may be cost-saving depending on the program chosen.

Keyphrases

atrial fibrillation
heart failure
coronary artery disease
percutaneous coronary intervention
acute coronary syndrome
drug delivery
mitral valve